Sector News

Roche forms 21-site I/O R&D network, commits $100M

November 17, 2016
Life sciences

Roche has put together a cancer immunotherapy research network and committed up to $100 million to support collaborations between the 21 academic centers. Members of the network will share data, expertise and technology with a view to accelerating the progress of programs out of the lab and into the clinic.

The network, dubbed the global cancer immunotherapy Centers of Research Excellence (imCORE), formalizes the links between Roche, Genentech and the academic centers. Roche is hoping linking and supporting the research sites will lead to new ideas about how to increase the proportion of patients who respond to cancer immunotherapies. So far, the effects of immunotherapies on tumors have ranged from very powerful to non-existent.

Roche is looking outside its walls for help solving the problem.

“We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world,” Roche CMO Dr Sandra Horning said in a statement.

The Swiss Big Pharma is putting up $100 million to support collaborations within the network. That sum, while tiny in the context of Roche’s $8 billion biopharma R&D budget, is meaningful for the type of projects being pursued within imCORE. The sweet spot for the network spans from basic research, through preclinical and into human studies. Roche plans to maximize the bang for its buck by pooling and sharing data generated by imCORE projects.

That approach is in keeping with the prevailing culture in oncology research since the White House’s Cancer Moonshot 2020 program shunted data sharing up the agenda. On paper, the model opens the door to advances downstream of the completion of a study by allowing a network of researchers to bring their own expertise and experience to the data.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach